RHHVF (Roche Holding AG) Total Current Assets : $37,625 Mil (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Roche Holding AG Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Roche Holding AG's total current assets for the quarter that ended in Jun. 2024 was $37,625 Mil.

Roche Holding AG Total Current Assets Historical Data

The historical data trend for Roche Holding AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Total Current Assets Chart

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

31,807.45

37,080.14

38,682.95

36,298.84

38,674.84

Roche Holding AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial															31,252.32	36,298.84	34,402.49	38,674.84	37,624.75

Roche Holding AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Roche Holding AG's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	12153.099	+	15104.07	+	8960.453	+	2457.216
	=	38,675

Roche Holding AG's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	9861.267	+	13619.378	+	8889.013	+	5255.09
	=	37,625

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Roche Holding AG (OTCPK:RHHVF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Roche Holding AG's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9861.267	-	70384.874	+	0.75 * 13619.378	+	0.5 * 8889.013
=	-45,865

Roche Holding AG Total Current Assets Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHVF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

RHHBY:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0TDF:UK 0QQ6:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.